Cystic fibrosis [NEW TOPIC PAGE]

Main|Search|PHGKB






Last Posted: Oct 25, 2018

---

• [Neonatal screening for cystic fibrosis : towards a national implementation in Belgium in 2019].
  Boboli H et al. Revue medicale de Liege 2018 Oct 73(10) 497-501
• Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis.
  Smith Daniel J et al. Gene 2018 Oct 68312-17
• Triple CFTR Modulator Therapy for Cystic Fibrosis.
  Holguin Fernando et al. The New England journal of medicine 2018 Oct
• VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
  Keating Dominic et al. The New England journal of medicine 2018 Oct
• [Rare diseases in post-genomic era.]
  Pulciani Simonetta et al. Recenti progressi in medicina 108(7) 307-315
• ETHICS EVALUATION REVEALING DECISION-MAKER MOTIVES: A CASE OF NEONATAL SCREENING.
  Raimond Véronique et al. International journal of technology assessment in health care 2018 Jan 34(2) 189-195
• New therapies pack a triple-drug punch to treat cystic fibrosis
  A Cunningham, Science News, October 19, 2018
• VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
  D Keating et al, NEJM, October 18, 2018
• Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.
  Grosse Scott D et al. Healthcare (Basel, Switzerland) 2015 3(4) 1133-57
• The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
  Grosse Scott D et al. The Milbank quarterly 2016 94(2) 366-91

more